Overcoming Cancers Resistant to HER-2 Antibodies

— —

Benjamin Bonavida (Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, USA)

Overcoming Cancers Resistant to HER-2 Antibodies

Benjamin Bonavida (Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, USA)

$272.95

Hardback

Forthcoming
Pre-Order now

QTY:

English

Academic Press Inc
01 June 2024

Biotechnology industries; Personal & public health; Oncology

Series: Breaking Tolerance to Antibody-Mediated Immunotherapy

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.

This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.

Edited by: Benjamin Bonavida (Professor Department of Microbiology Immunology and Molecular Genetics David Geffen School of Medicine University of California Los Angeles USA)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 235mm, Width: 191mm,
ISBN: 9780128164082
ISBN 10: 0128164085
Series: Breaking Tolerance to Antibody-Mediated Immunotherapy
Pages: 250
Publication Date: 01 June 2024
Audience: Professional and scholarly , Undergraduate
Format: Hardback
Publisher's Status: Forthcoming

1. General Introduction of Cancers responding to FDA-approved anti-HER2 antibodies (Trastuzumab)1B. Antibody Induction of Anticancer Immunity 2. Sensitization of Trastuzumab Response by the Combination with Pentuzumab 3. Sensitization by Lapatinib of Trastuzumab Resistance 4. Sensitization by Ganetespib (HSP90 inhibitor) of Trastuzumab Resistance 5. Sensitization by Paclitaxel of Trastuzumab Resistance 6. Sensitization by Celecoxib of Trastuzumab Resistance 7. Sensitization by Emantasine (T-DM1) of Trastuzumab Resistance 8. Sensitization by Anti-apoptotic Inhibitors of Trastuzumab Resistance 9. Sensitization by Kinase Inhibitors of Trastuzumab Resistance 10. Sensitization by Vinorelbine of Trastuzumab Resistance 11. Sensitization by Fulvestrant of Trastuzumab Resistance 12. Sensitization by IFF-1 Inhibitors of Trastuzumab Resistance 13. Sensitization by Liposomal Doxorubicin of Trastuzumab Resistance 14. Sensitization by Combination of Immunotherapy and Trastuzumab 15. Sensitization by Radiotherapy of Trastuzumab Resistance 16. Sensitization by Chemotherapy of Trastuzumab Resistance 17. New Development of Targeted Anti-HER-2 Antibodies

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).